1 2 9 1 a r t I C l e S eCBs, including anandamide (AEA) and 2-arachidonoylglycerol (2-AG), are lipid-derived signaling molecules that activate the cannabinoid receptors CB 1 and CB 2 1-3 . eCBs have been implicated in many physiological and pathological processes, including metabolic regulation 4,5 , pain modulation 6,7 , cognitive and memory function 8 , stress and anxiety modulation 9,10 , and immunological processes, such as inflammation 11,12 , tumor progression 13,14 and bone remodeling 15 . Augmentation of eCB signaling via inhibition of the eCB-degrading enzymes fatty acid amide hydrolase (FAAH), which regulates AEA levels 16 , and monoacylglycerol lipase (MAGL), which regulates 2-AG levels 17 , has demonstrated preclinical efficacy in a variety of pathological processes, including mood and anxiety disorders 10,18-23 . However, both strategies lack selectivity for modulating eCB lipids over structurally related non-eCB lipids. Elucidation of previously unknown molecular targets and pharmacological approaches to augment eCB signaling with higher selectivity could have broad therapeutic implications 24-26 .
regulation of eCB signaling, direct evidence for the in vivo regulation of eCBs by COX-2 is lacking, as is a viable pharmacological strategy to modulate eCB levels via COX-2 inhibition without also affecting prostaglandin synthesis.
We recently reported that rapid-reversible inhibitors of COX-2 selectively inhibited the oxygenation of 2-AG and AEA with much lower half maximal inhibitory concentrations than for arachidonic acid, a phenomenon we termed substrate-selective inhibition of COX-2 (refs. 33, 34) . Despite these initial findings, neither the molecular basis for substrate-selective inhibition nor the in vivo efficacy of substrate-selective COX-2 inhibitors (SSCIs) to augment eCB signaling has been demonstrated. Here we elucidated the molecular determinants of substrate-selective pharmacology in vitro and developed, to the best of our knowledge, the first in vivo biologically active SSCI with anxiolytic effects in preclinical models.
RESULTS

Development of in vivo bioactive SSCIs
To develop in vivo biologically active SSCIs, we used site-directed mutagenesis of COX-2 active site residues to identify the key molecular interactions required for SSCIs. Previous studies have established that mutations of Arg120 and Tyr355 of COX-2 markedly reduce the ability of the COX inhibitor indomethacin to inhibit arachidonic acid oxygenation by eliminating its ability to ion-pair and hydrogen bond with COX-2 (ref. 35 ). However, we found that indomethacin still potently inhibited eCB oxygenation by the COX-2 R120Q and Y355F mutants ( Fig. 1a-d) . This indicates that, although ion-pairing and 1 2 9 2 VOLUME 16 | NUMBER 9 | SEPTEMBER 2013 nature neurOSCIenCe a r t I C l e S hydrogen-bonding with Arg120 and Tyr355 are critical for indomethacin inhibition of arachidonic acid oxidation to prostaglandins, they are much less important for inhibition of eCB oxygenation.
We next synthesized and screened a small library of tertiary amide derivatives of indomethacin, which have a reduced capacity to ion-pair and hydrogen bond with Arg120 and Tyr355. Each of the tertiary amides inhibited eCB oxygenation by COX-2, but did not inhibit arachidonic acid oxygenation (Supplementary Table 1 ). The morpholino amide of indomethacin, LM-4131 (also known as BML-190; Fig. 1e ), was effective at inhibiting eCB oxygenation by purified mCOX-2 and by COX-2 in lipopolysaccharide-activated RAW 264.7 macrophages without inhibiting arachidonic acid oxygenation ( Fig. 1f,g) . Moreover, LM-4131 increased 2-AG levels in stimulated RAW 264.7 macrophages in a concentration-dependent manner without increasing arachidonic acid levels, providing cellular evidence for substrate-selective pharmacology of LM-4131 ( Fig. 1h) . Notably, LM-4131 did not inhibit other eCB metabolizing/synthetic enzymes, including FAAH, MAGL and DAGLα ( Fig. 1i-k) . Thus, LM-4131 exhibits multiple properties desirable in a SSCI, and we selected it for subsequent in vivo studies.
In vivo augmentation of eCB levels by LM-4131 via SSCI
To assess the ability of LM-4131 to modulate eCB levels in vivo, we administered LM-4131 to male ICR mice via intraperitoneal injection and analyzed levels of eCBs, prostaglandins and arachidonic acid 2 h after administration. We found that LM-4131 significantly increased whole brain AEA levels at 3 (P < 0.01) and 10 (P < 0.0001) mg per kg of body weight with a nonsignificant trend to increase 2-AG levels at the highest dose (P = 0.10; Fig. 2a,b) . LM-4131 did not affect arachidonic acid levels or prostaglandin levels at any of the doses that we tested ( Fig. 2c,d) , indicating that the substrate selectivity of LM-4131 was retained in vivo. To quantify the magnitude of the increase in brain eCBs induced by LM-4131 treatment, we conducted a meta-analysis of data obtained from 12 cohorts of mice, normalizing eCB levels in each mouse to mean eCB levels in the respective vehicle control group. This analysis revealed that, on average, treatment with 10 mg per kg LM-4131 significantly increased AEA levels to 139% of those observed when treated with vehicle (P < 0.0001), and increased 2-AG levels to 109% of those observed when treated with vehicle (P < 0.01; Fig. 2e,f) . Analysis of brain extracts revealed the presence of LM-4131, but not indomethacin, after LM-4131 treatment ( Supplementary  Fig. 1 ). Thus, LM-4131 selectively increased eCB levels without affecting arachidonic acid or prostaglandin levels and was present in the brain 2 h after intraperitoneal injection.
To confirm that the in vivo substrate-selective profile of LM-4131 is unique relative to other COX inhibitors, we determined the ability of indomethacin (10 mg per kg, a nonselective COX-1/COX-2 inhibitor and the parent compound of LM-4131), the COX-2 selective inhibitor NS-398 (10 mg per kg) and the COX-1 selective inhibitor SC-560 (10 mg per kg) to modulate eCB, arachidonic acid and prostaglandin levels in vivo. LM-4131 (P < 0.0001), indomethacin (P < 0.0001), NS-398 (P < 0.001) and SC-560 (P < 0.01) significantly increased AEA levels, whereas only LM-4131 (P < 0.01) and indomethacin (P < 0.01) significantly increased 2-AG levels (Fig. 2g,h) . LM-4131 did not affect npg a r t I C l e S arachidonic acid levels, whereas indomethacin (P < 0.001), NS-398 (P < 0.01), and SC-560 (P < 0.01) all significantly increased arachidonic acid levels ( Fig. 2i) . Indomethacin, NS-398 and SC-560 (P < 0.0001 for all), but not LM-4131, markedly decreased brain prostaglandin levels (Fig. 2j) . These data indicate that the in vivo substrate-selective pharmacological profile of LM-4131 is unique and is not shared by traditional COX inhibitors. We next confirmed COX-2 as the in vivo molecular target mediating the increase in brain eCBs observed after LM-4131 treatment using COX-2 knockout (Ptgs2 −/− ) mice. LM-4131 (10 mg per kg) significantly increased AEA (P < 0.01) and 2-AG (P < 0.05) levels in wildtype, but not Ptgs2 −/− , littermates ( Fig. 2k,l) . Notably, Ptgs2 −/− mice had significantly higher brain AEA levels than wild-type littermates at baseline (P < 0.0001). Lastly, LM-4131 did not affect arachidonic acid or prostaglandin levels in wild-type or Ptgs2 −/− mice ( Fig. 2m,n) . These data confirm that LM-4131 increases brain eCB levels via a COX-2-dependent mechanism and that COX-2 substantially regulates basal brain AEA levels in vivo.
LM-4131 selectively increases eCBs over non-eCB lipids
One major limitation of currently available eCB degradation inhibitors is their lack of selectivity for eCBs over related non-eCB lipids. FAAH inhibition increases AEA levels, but also increases N-acylethanolamides (NAEs; oleoylethanolamide, palmitoylethanolamide and stearoylethanolamide) levels. Similarly, MAGL inhibition increases 2-AG levels, but also increases the levels of related monoacylglycerols (MAGs), including 2-oleoylglycerol, 2-palmitoylglycerol and 2-stearoylglycerol. Given the selectivity of COX-2 for arachidonic npg a r t I C l e S acid-containing lipids, we hypothesized that LM-4131 would be selective for increasing AEA and 2-AG levels over those of other NAEs and MAGs. To test this hypothesis, we conducted targeted lipid profiling of NAEs and MAGs after LM-4131 treatment. As expected, LM-4131 significantly increased brain AEA levels (P < 0.0001; Fig. 3a ), but not those of any other NAE. In contrast, the FAAH inhibitor PF-3845 (10 mg per kg) 36, 37 robustly increased the levels of all NAEs, including AEA (Fig. 3b) . These data strongly suggest that LM-4131 selectively increases brain AEA levels over those of other NAEs and that its mechanism of action is not via off-target FAAH inhibition, as we would expect to see increases in the levels of other NAEs if this were the case.
To further exclude FAAH inhibition as contributing to the AEAelevating effects of LM-4131, we conducted several additional experiments. First, we found that LM-4131 caused a significant additional increase in AEA levels (P < 0.01) when combined with the FAAH inhibitor PF-3845 compared with PF-3845 treatment alone ( Fig. 3c ), suggesting different mechanisms of action. Second, we found that LM-4131 did not affect levels of any NAE in the liver, which has very high FAAH expression, whereas PF-3845 caused robust increases in the levels of all NAEs (Fig. 3d) . Lastly, we found that LM-4131 increased brain AEA levels in wild-type and Faah −/− mice to a similar extent ( Fig. 3e) . Taken together with our biochemical finding that LM-4131 does not inhibit FAAH activity in vitro, these converging in vivo data strongly suggest a unique COX-2-mediated mechanism of action of LM-4131 to increase AEA levels.
We also tested the selectivity of LM-4131 for 2-AG over other MAGs compared with the MAGL inhibitor JZL-184 (40 mg per kg). Although LM-4131 (10 mg per kg) significantly increased brain 2-AG levels (P < 0.05), it did not affect the levels of any other MAG (Fig. 3f) . In contrast, the MAGL inhibitor JZL-184 increased the levels of 2-AG and three other MAG species (Fig. 3g) . Furthermore, LM-4131 produced an additional significant increase in 2-AG levels after JZL-184 treatment (P < 0.05) compared with JZL-184 alone (Fig. 3h) . Combined with our in vitro data that LM-4131 does not affect MAGL activity, these in vivo data strongly suggest that the ability of LM-4131 to increase 2-AG levels is not mediated via MAGL inhibition.
Lastly, we wanted to determine the selectivity of the regulation of basal brain eCBs by COX-2 over related non-eCB NAEs. We therefore examined the effect of LM-4131 on brain NAEs in wild-type and Ptgs2 −/− mice. We again found that LM-4131 significantly increased brain AEA levels in wild-type mice (P < 0.001), but not those of other NAEs (Fig. 3i) , and that Ptgs2 −/− mice had increased levels of AEA (P < 0.001), but not those of other NAEs. These data confirm a key role for COX-2 in the selective regulation of basal AEA over other non-eCB NAEs.
Similar to other eCB-degrading enzymes, including FAAH and MAGL, COX-2 is expressed in many tissues. We therefore tested npg a r t I C l e S the effect of LM-4131 on eCB, NAE, MAG and prostaglandin levels in a variety of peripheral tissues. LM-4131 (10 mg per kg) significantly increased AEA levels in the stomach (P < 0.05), small intestine (P < 0.05), kidney (P < 0.0001) and lung (P < 0.001), but not in the heart (Fig. 4) or liver (Fig. 3d) . In contrast, LM-4131 did not affect levels of any other NAE in any tissue. Similarly, LM-4131 had no effect on 2-AG or any other MAG in any of the peripheral tissues that we examined ( Fig. 4) . To confirm that LM-4131 retained substrateselective pharmacology outside the CNS, we measured levels of prostaglandins in each tissue after LM-4131 and indomethacin treatment.
As expected, indomethacin robustly decreased prostaglandin levels in all of the tissues examined (P < 0.0001 for stomach, heart, kidney and lung, P < 0.001 for intestine), whereas LM-4131 had no effect on prostaglandin levels in any of the tissues examined (Fig. 4) . These data indicate that SSCI can selectively augment AEA levels without affecting non-eCB NAE levels in peripheral tissues and that LM-4131 retains in vivo substrate selectivity in peripheral tissues.
LM-4131 reduces anxiety via eCB augmentation
Given that eCB augmentation via FAAH inhibition has been suggested to represent a new approach to the treatment of mood and anxiety disorders 22, 26 , we assessed the behavioral effects of LM-4131 in pre-clinical models of anxiety. Previous work has shown that FAAH inhibitors are anxiolytic in the novel open-field arena 38 , and, consistent with this, we found that the FAAH inhibitor PF-3845 (10 mg per kg) increased center distance traveled and center time in the open-field arena (Fig. 5a) . Notably, LM-4131 (10 mg per kg) also increased center distance traveled and center time ( Fig. 5b) , suggesting that it has similar behavioral effects to those of a FAAH inhibitor with respect to reducing anxiety in this assay. To test the hypothesis that all COX inhibitors that increase brain AEA exert a similar behavioral profile to LM-4131, we tested the effects of indomethacin (10 mg per kg), NS-398 (10 mg per kg) and SC-560 (10 mg per kg) in the open-field arena ( Supplementary Fig. 2a,b) . Indomethacin and NS-398, which both increased brain AEA levels, increased center time and center distance traveled in the open-field arena, suggestive of an anxiolytic behavioral effect. However, SC-560, which had only marginal effects on brain AEA levels, did not have any behavioral effect in this assay (Supplementary Fig. 2c) .
To determine whether the behavioral effects of LM-4131 were mediated by substrate-selective inhibition of COX-2, we tested the behavioral effects of LM-4131 in Ptgs2 −/− mice and wild-type littermates. Although resulting in a normal anxiolytic-like response in wildtype littermates (Fig. 5c-e ), LM-4131 did not produce any behavioral effects in Ptgs2 −/− mice ( Fig. 5c-e) , consistent with the lack of change in AEA levels seen after LM-4131 administration in Ptgs2 −/− mice. Notably, Ptgs2 −/− mice showed a slight anxiolytic phenotype relative to wild-type littermates on center time spent in the open field ( Supplementary Fig. 3) ; however, the exact mechanisms subserving this effect remain unknown.
Given that the anxiolytic effects of FAAH inhibition are mediated via AEA acting on CB 1 cannabinoid receptors 22, 39 , we next tested the role of CB 1 receptors in the anxiolytic-like behavioral effects of LM-4131 in the open field arena. Although it again exerted anxiolytic actions in vehicle-pretreated mice, LM-4131 had no behavioral effect in mice treated with the CB 1 receptor antagonist Rimonabant at 3 mg per kg ( Fig. 5f-h) . Furthermore, LM-4131 did not produce any behavioral effect in CB 1 receptor knockout mice (Cnr1 −/− ; Supplementary Fig. 4a ). To verify that LM-4131 actually increased eCB levels in Cnr1 −/− mice, we analyzed the eCB levels and prostaglandin levels in Cnr1 −/− mice after LM-4131 treatment and found that LM-4131 increased AEA and 2-AG levels in the brains of Cnr1 −/− mice and had no effect on prostaglandin levels (Supplementary Fig. 4b) . These data suggest that the behavioral effects of LM-4131 are mediated via substrate-selective inhibition of COX-2, which selectively increases brain eCB levels, leading to increased activation of central CB 1 receptors and anxiolytic behavioral effects.
To further assess the anxiolytic-like effects of eCB augmentation by LM-4131, we analyzed the effects of LM-4131 and the FAAH inhibitor PF-3845 in the light-dark box and the elevated plus-maze. In the light-dark box test, we found that PF-3845 (10 mg per kg) and LM-4131 (10 mg per kg) both significantly increased light-zone (Fig. 6) . Notably, the anxiolytic effects of LM-4131 were again blocked by the CB 1 receptor antagonist Rimonabant (3 mg per kg), indicating that the behavioral effects were mediated via CB 1 receptor activation ( Fig. 6d-f ). In the elevated plusmaze, both PF-3845 (10 mg per kg) and LM-4131 (10 mg per kg) significantly reduced open arm latency (P < 0.01 for PF-3845 and P < 0.0001 for LM-4131; Supplementary Fig. 5 ), but did not affect other parameters, including total distance traveled. Overall, the effects of LM-4131 closely mirrored the behavioral profile of PF-3845 in all of the anxiety measures that we examined, suggesting that SSCIs can exert anxiolytic actions via eCB augmentation in a similar manner to FAAH inhibition. These studies provide a proof-of-concept validation that SSCIs could represent a class of COX-2-based anxiolytic agents that exert anxiolytic actions via eCB activation. npg a r t I C l e S Finally, we examined the relative cannabimimetic effects of LM-4131 in vivo. Exogenous activation of CB 1 receptors produces a classical 'tetrad' of behavioral effects that are characterized by hypolocomotion, analgesia, catalepsy and hypothermia 40 . Our open field data indicate that LM-4131 does not cause hypolocomotion, and additional studies revealed that LM-4131 did not cause hypothermia, catalepsy or antinociception in the hot plate test (Fig. 7a-c) . In contrast, the CB 1 agonist Win-55212-2 induced hypothermia, catalepsy and anti-nociception ( Fig. 7a-c) . LM-4131 also did not induce memory deficits in the novel object recognition assay when administered before object memory retrieval (Fig. 7d) . We observed that LM-4131 did not cause gastrointestinal hemorrhage, a primary adverse effect of COX-1/2 inhibitors, including indomethacin, the parent drug of LM-4131 ( Supplementary Fig. 6 ). Taken together, these data indicate that LM-4131 induces a subset of behavioral effects that are mediated via eCB activation, but does not cause overt cannabimimetic effects and does not cause overt gastrointestinal toxicity observed with many traditional COX inhibitors including indomethacin.
DISCUSSION
Pharmacological approaches to augment eCB signaling have thus far focused on inhibition of FAAH and MAGL. Both approaches have been validated to robustly augment eCB levels in vivo 17, 22 and exert preclinical therapeutic effects in a variety of pathological conditions. However, both approaches increase non-eCB lipids (NAEs for FAAH inhibition and MAGs for MAGL inhibition) that have biological actions at targets other than cannabinoid receptors 41 . We found that COX-2 is a key regulator of eCB levels in vivo and that SSCIs represent a viable alternative approach to augment eCB levels with a high degree of selectivity. In contrast with traditional COX inhibitors, only the SSCI LM-4131 increased AEA levels without affecting central or peripheral prostaglandins. These data validate the in vivo substrate selectivity of LM-4131 and provide a new and effective pharmacological strategy to selectively augment central AEA signaling via COX-2 inhibition. Although LM-4131 treatment had an overall significant effect on 2-AG levels, it was quite small and not recapitulated in every experiment; thus, any biological relevance of this effect remains to be determined. Our data suggest that COX-2 preferentially regulates AEA over 2-AG. The larger effects of COX-2 inhibition on AEA over 2-AG may be related to the closer proximity between COX-2 and the site of AEA biosynthesis and may explain its relative lack of overt cannabimimetic effects 36 . In support of this notion, FAAH, which is the primary metabolic regulator of AEA, is localized to the same postsynaptic cellular compartment as COX-2 (ref. 42 ). Furthermore, LM-4131 did not affect levels of non-eCB NAEs or MAGs in the brain or periphery, providing enhanced selectivity over FAAH and MAGL inhibition for eCB augmentation. That LM-4131 was able to increase AEA levels in several peripheral tissues tested suggests that COX-2 has a widespread role in the regulation of AEA signaling.
Consistent with findings that elevating AEA levels via FAAH inhibition exerts anxiolytic-like actions in preclinical models 22, 38, 39, 43 , we also found that LM-4131 decreased anxiety-like behaviors using multiple validated assays. Our data suggest that SSCIs could represent a viable approach to the treatment of mood and anxiety disorders; however, further studies are clearly required to confirm this suggestion. Notably, COX-2 inhibition has demonstrated clinical antidepressant efficacy as an adjunct to traditional antidepressants 44 . Our data raise the possibility that these effects could be at least partially a result of augmentation of brain eCB signaling.
In addition to having beneficial effects in the brain, the substrate selectivity of LM-4131 could potentially reduce some common side effects mediated by inhibition of prostaglandin synthesis by traditional NSAIDs. Gastrointestinal prostaglandin production is essential for stimulation of mucosal bicarbonate and mucus secretion as well as increasing mucosal blood flow 45 . As such, traditional NSAIDs are associated with serious gastrointestinal complications. Our data indicate that LM-4131 does not cause overt gastrointestinal hemorrhage, as is seen with indomethacin. Furthermore, the cardiovascular toxicity of COX inhibitors is well-established and has been suggested to be mediated by inhibition of prostaglandin synthesis 46 . As such, SSCIs may be devoid of such toxicity, as they do not affect prostaglandin levels in the heart or lung. Additional research will be required to evaluate the side effects of SSCIs relative to those of traditional COX inhibitors.
We found that COX-2 is a key regulator of brain eCB signaling in vivo and that substrate-selective inhibition of COX-2 could represent a pharmacological approach to the treatment of anxiety disorders. Moreover, given the numerous pathological processes in which dysregulation of eCB signaling has been demonstrated, coupled with the high degree of selectivity of SSCIs for eCBs over related non-eCB lipids, we suggest that SSCIs could represent a previously unknown class of pharmaceutical agents with broad therapeutic potential.
METHODS
Methods and any associated references are available in the online version of the paper. In vitro enzyme purification and activity assays. Wild-type, R120Q and Y355F COX-2 were expressed in insect cells and purified as described previously 48 .
In vitro COX-2 inhibition assays were performed as previously described 33 .
The RAW 264.7 macrophage inhibition assay was performed as previously described 49 . MAGL was purified using BL21(DE3) pLysS E. coli transformed with pET-45b(+) plasmid containing human MGL-His. Cells were grown at 37 °C to a density of 0.7 OD and protein expression was induced with IPTG (1 mM). Cells were harvested 4 h later and proteins were purified using Ni-NTA Agarose (Qiagen) as previously described 50 . After purification, the protein was dialyzed overnight at 4 °C into buffer containing 0 mM HEPES and 0.01% Triton X-100 (vol/vol). MAGL inhibition was assessed as previously described 50 . Humanized rat FAAH was a generous gift of R. Stevens and B. Cravatt (The Scripps Research Institute). FAAH inhibition was assessed as previously described 51 . Human DAGLα in pcDNA3.1D was expressed in HEK293T cells for 24 h then harvested and membranes prepared as described previously 52 . DAGLα activity was assessed using 5 µg of membrane protein in a 50 µl reaction of assay buffer containing 50 mM MES (pH 6.5) and 2.5 mM CaCl 2 . 1-stearoyl-2-arachidonoyl glycerol was added directly from a 100% methanol stock for a final concentration of 250 µM (5% final concentration of methanol in reaction). The reaction was terminated after 15 min by the addition of 200 µl methanol containing 125 pmol 2-AG-d 8 . The samples were spun down at 2,000 g and the soluble material injected directly for LC-MS/MS analysis.
Animals. We used 5-7-week-old male ICR mice for all experiments with the exception of knockout mice (Harlan). Mice were housed 5 per cage. All behavioral tests were conducted during the light cycle between 0900 and 1700. Knockout and wild-type littermate controls for Faah −/− and Ptgs2 −/− mice were derived from heterozygote breeding pairs, bred and genotyped as previously described 53 . Cnr1 −/− mice were bred from homozygote breeding pairs and genotyped as previously described 54 . All transgenic mice were on an ICR background. Mice were group-housed on a 12-h:12-h light-dark cycle (lights on at 06:00), with food and water available ad libitum. All animal studies were approved by the Vanderbilt Institutional Animal Care and Use Committee and conducted in accordance with the US National Institutes of Health Guide for the Care and Use of Laboratory animals.
Tissue preparation and lipid extraction. Mice were killed by cervical dislocation and decapitation. The brain, lungs, liver, stomach, small intestines and kidneys were then rapidly removed and frozen on a metal block in dry ice. The tissue was then placed in a tube and stored at −80 °C until extraction, usually 1 d after harvesting. For prostaglandin and eCB analysis, lipid extraction from tissue was carried out as described previously 55 .
open field test. Mice were tested for open-field activity in a novel environment 1 h after intraperitoneal injection of compound as previously described 20 The mice were placed into the same rectangular chamber 24 h later with two identical sample objects, yellow rubber ducks, for 10 min so that the mice could become familiar with the objects. During training, the sample objects were placed in opposite corners in the back of the chamber 5 cm from each wall and secured by weight to the floor of the chamber. The mice were placed into the chamber again 24 h later with one sample or familiar object and a novel object, a white leaf statue, for 5 min. During testing, the objects were placed in opposite corners in the back of the chamber 5 cm from each wall and secured by weight to the floor of the chamber. The mice were treated 2 h before testing with either vehicle or the COX-2 inhibitor, LM-4131 (10 mg per kg), by intraperitoneal injection. To determine exploration time with the sample and novel objects, each mouse was timed when interacting with the sample or novel object when the nose of the mouse was in contact with the object or directed toward the object within a 2-cm distance of the object. The time the mouse spent on top of the objects was not included in the exploration time analyses. In addition, a discrimination ratio (for example, ratio of a mouse's interaction with a novel object to that mouse's total interaction with both sample and novel objects) was determined. If the discrimination ratio was >0.5, it was considered that the mouse interacted more with the novel object than with the sample or familiar object. mass spectrometry analysis. Analytes were quantified using LC-MS/MS on a Quantum triple-quadrupole mass spectrometer in positive-ion mode using selected reaction monitoring. Detection of eicosanoids was performed as previously described 56 . For fatty acid analysis, the mobile phases used were 80 µM AgOAc with 0.1% acetic acid in H 2 O (vol/vol, solvent A) and 120 µM AgOAc with 0.1% acetic acid in MeOH (vol/vol, solvent B). The analytes were eluted using a gradient from 20% A to 99% B over 5 min. The transitions used were m/z 300→282 for palmitoylethanolamide, m/z 328→310 for stearoylethanolamide, m/z 434→416 for oleoylethanolamide, m/z 456→438 for AEA, m/z 464→ 446 for AEA-d 8 , m/z 331→257 for 2-palmitoylglycerol, m/z 359→285 for 2-stearoylglycerol, m/z 463→389 for 2-oleoylglycerol, m/z 485→411 for 2-AG, m/z 493→419 for 2-AG-d 8 , m/z 519→409 for arachidonic acid, and m/z 527→ 417 for AA-d 8 . Peak areas for the analytes were normalized to the appropriate internal standard and then normalized to tissue mass for in vivo samples.
Statistical analysis.
Statistical analysis was performed using GraphPad Prism Version 6.0c. For determining statistical significance between groups, a two-tailed t test, one-way ANOVA or two-way ANOVA with a Sidak's post-test analysis, or multiple t tests with Holm-Sidak α correction for multiple comparisons was used throughout. F and P values shown correspond to the value obtained from the test used. Large data sets of normalized brain AEA and prostaglandin levels (n > 100) showed a normal distribution using D' Agostino & Pearson omnibus normality test. 2-AG did not, but visual inspection of the distribution in of 2-AG levels in Figure 2f did not show obvious outliers or heavy tails. No routine analysis of differences in data set variance was conducted; thus, t tests did not assume equal variances (Welch correction). No treatment blinding was conducted. Sample sized were based on previous studies 55 . N for each group represents number of mice, that is, independent biological replicates. Mice were arbitrarily assigned to treatment group in a manner that resulted in approximately equal sample sized npg per treatment group. Each treatment group was represented at least once per cage of mice. No mice were excluded from the statistical analysis. 
